Synthetic macrocycles offer exceptional potential as therapeutics, combining the ability to engage challenging biological targets with favorable drug-like properties. However, most high-throughput dis...

Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach to understand and treat neurodegenerative d...

McGettrick et al. provide a succinct yet broad overview of the immunometabolite itaconate as an immunomodulatory molecule.

Predict molecular properties (ADMET, permeability, kinase binding, etc.) from SMILES strings or CSV files.

BCL2 is a key pro-survival protein that is overexpressed in many cancers. The first generation BCL2 inhibitor venetoclax has proved highly effective i…

Drug discovery is adapting to novel technologies such as data science, informatics, and artificial intelligence (AI) to accelerate effective treatment development while reducing costs and animal exper...

In 2014, the Illuminating the Druggable Genome programme was launched to promote the exploration of currently understudied but potentially druggable proteins. This article discusses how the systematic collection and processing of a wide array of biological and chemical data as part of this programme has enabled the development of evidence-based criteria for tracking the target development level of human proteins, which indicates a substantial knowledge deficit for approximately one out of three proteins in the human proteome. It also highlights the nature of the unexplored therapeutic opportunities for major protein families.

YouTube video by Universität Bern